Emergent BioSolutions Completes Sale of Baltimore Facility to Syngene
Deal News | Mar 19, 2025 | Globenewswire
Emergent BioSolutions has concluded the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million, further streamlining its operations while retaining future manufacturing service rights. Financial adviser Truist and legal counsel Covington & Burling LLP assisted Emergent in this transaction. This strategic move aligns with Emergent’s long-term growth objectives, enabling it to focus on its core operations while maintaining the ability to meet future demand spikes, especially in pandemic response scenarios.
Sectors
- Biopharmaceuticals
- Contract Research and Manufacturing
Geography
- United States – Emergent BioSolutions is headquartered in Gaithersburg, Maryland, and the Baltimore-Bayview facility is located in the U.S.
- India – Syngene International, the acquirer, is an Indian company, indicating cross-border involvement in the transaction.
Industry
- Biopharmaceuticals – Emergent BioSolutions operates within the biopharmaceuticals industry, focusing on health threats such as pandemics and bioterrorism.
- Contract Research and Manufacturing – Syngene International operates in this sector by acquiring assets to enhance its service offerings in drug development and manufacturing.
Financials
- $36.5 million – The sale price received by Emergent BioSolutions for the Baltimore facility, subject to customary post-closing adjustments.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Emergent BioSolutions Inc. | Selling Company | Company | A biopharmaceutical company focused on developing products to protect and enhance life by addressing public health threats. |
| Syngene International | Bidding Company | Company | A contract research organization engaged in integrated drug discovery and development services to pharmaceutical and healthcare sectors. |
| Truist | Financial Advisor | Company | Served as the financial advisor to Emergent BioSolutions during the sale transaction. |
| Covington & Burling LLP | Legal Advisor | Company | Provided legal counsel to Emergent BioSolutions for the transaction. |